BOTOX® in the Treatment of Crow's Feet Lines in Japan

Study Identifier
191622-114
CT.gov Identifier
NCT01797081
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Facial Aesthetics - Toxins
    • Study Drug
  • botulinum toxin Type A (24 U)
  • botulinum toxin Type A (12 U)
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    20 - 64 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    -Moderate to severe Crow's Feet Lines
    Exclusion Criteria:
    * Current or previous botulinum toxin treatment of any serotype * Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis * Facial laser or light treatment for cosmetic purposes, microdermabrasion, superficial peels, or topical retinoid therapy or hormone cream within 3 months * Laser treatment or phototherapy of the face for medical purposes, blepharoplasty, brow-lift or related procedure, periorbital permanent make-up, or oral retinoid therapy within one year * Medium-depth or deep facial peels within 5 years * Prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift, periorbital treatment with fillers, implantation or transplantation)

    Protocol Summary

    This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).

    Study Locations

    Location
    Status
    Location
    Tokyo, Japan
    Status
    Not applicable